Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).

The study evaluated predictors of quality of life for patients with acute myeloid leukemia (AML) and high risk MDS, comparing quality of life scores between two treatment groups: intensive induction chemotherapy and outpatient hypomethylating agents or clinical trials.

Tinsley says the study found that patients who received induction chemotherapy saw an improvement in their quality of life score. While patients who received outpatient therapy saw a decrease in quality of life, those findings were not statistically significant.

Sara M. Tinsley, MS, PhD, ARNP, AOCN

Articles

Sara Tinsley Discusses Quality of Life in Patients with High-Risk MDS